Sotorasib in KRAS -Mutated Colorectal Cancer
New England Journal of Medicine · 2024
DOI: 10.1056/nejmc2406109 ↗Kurz gefasst
Leserbrief in der Zeitschrift New England Journal of Medicine, 2024. Verfasst von Tito Fojo. Beteiligte Einrichtung: Columbia University, New York, NY atf2116@cumc.columbia.edu. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Proto-Oncogene Proteins p21(ras). Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 7 Literaturangaben.
Abstract (Originalsprache)
To the Editor: Regarding the report by Fakih et al. (Dec. 7 issue) 1 on the CodeBreaK 300 trial of sotorasib in KRAS -mutated colorectal cancer: examination of the data finds problems similar to those identified by the Food and Drug Administration in the CodeBreaK 200 trial of sotorasib in non–small-cell lung cancer. 2 The progression-free survival analysis suffers from asymmetric censoring that can disrupt randomization balance if patients who dropped out are predominantly in one trial group. In the first 2 months, data from 11 of 54 patients (20%) assigned to the standard-care group were censored, as compared with 2 patients in . . .
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Columbia University, New York, NY atf2116@cumc.columbia.edu.
Zitieren
APA
Fojo, T. (2024). Sotorasib in KRAS -Mutated Colorectal Cancer. New England Journal of Medicine. https://doi.org/10.1056/nejmc2406109
Vancouver
Fojo T. Sotorasib in KRAS -Mutated Colorectal Cancer. New England Journal of Medicine. 2024. doi:10.1056/nejmc2406109
BibTeX
@article{Fojo2024,
author = {Fojo, Tito},
title = {Sotorasib in KRAS -Mutated Colorectal Cancer},
journal = {New England Journal of Medicine},
year = {2024},
doi = {10.1056/nejmc2406109}
}
EUVIMED